Naloxegol
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Naloxegol (INN; NKTR-118), or PEGylated naloxol,[1] trade name Movantik, is a peripherally–selective opioid antagonist under development by AstraZeneca, licensed from Nektar, for the treatment of opioid-induced constipation.[2]
References
References
- ↑ Roland Seifert; Thomas Wieland; Raimund Mannhold (17 July 2006). G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity. John Wiley & Sons. p. 227. ISBN 978-3-527-60695-5. Retrieved 14 May 2012. Unknown parameter
|coauthors=ignored (help) - ↑ “Nektar | R&D Pipeline | Products in Development | CNS/Pain | Oral Naloxegol (NKTR-118) and Oral NKTR-119”. Retrieved 2012-05-14.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH